Published:
Iowa Resident Dies After Using Contaminated Blood Thinner
Iowa Resident Dies After Using Contaminated Blood Thinner
CHICAGO, May 14 /PRNewswire/ -- Last month a lawsuit was filed against
Deerfield, Illinois-based Baxter International Inc. on behalf ofDavenport,
Iowa resident, Mark Scott who suffered the tragic loss of his wife, Melissa
Scott, on November 30, 2007. The complaint was filed On April 1, 2008 in the
Circuit Court ofCook County by Nolan Law Group and alleges that Melissa
Scott's untimely death was caused by her exposure to Heparin Sodium Injection
Therapy. The complaint cites two counts of product liability and negligence on
the part of Baxter International.
The lawsuit filed by Nolan Law Group and Mark Scott asserts that Baxter
International was responsible for the manufacture, sale and distribution of a
product containing toxic chemicals. It also claims that the product was
manufactured with insufficient amounts of the active ingredient API and that
Baxter International failed to provide adequate warnings or instructions to
assist users in identifying adverse reactions.
Baxter's Heparin has been implicated in more than 400 life-threatening
incidents and may be responsible for as many as 81 deaths. In February 2008,
Baxter initiated a voluntary recall of nine lots of Heparin Sodium Injection
Multi-Dose Vials. According to Baxter International, they recalled the lots
due to a spike in adverse reports associated with the use of Baxter Heparin
Sodium Injections. After receiving additional reports of similar adverse
reactions from other lots of their Heparin Sodium Injection Products,Baxter
recalled their remaining multi-dose and single-dose vials, as well as HEP-LOCK
Heparin Flush Products.
It was around this same time that the Food & Drug Administration (FDA)
issued its initial Public Health Advisory warning doctors and other health
practitioners not to use Baxter Heparin products. The report stated that
serious injuries and deaths have been associated with the use of Heparin. The
adverse effects have included allergic or hypersensitivity-type reactions with
symptoms, such as low blood pressure, shortness of breath, nausea, vomiting,
diarrhea, and abdominal pain and death.
Since the original complaint was filed, the Food and Drug Administration
(FDA) has conducted a formal investigation in which they identified an unknown
contaminant found in the Baxter Heparin. In early April of 2008, researchers
confirmed the FDA's suspicion that the contaminant found in the Heparin is
Oversulfated Chondroitin Sulfate (OSCS), a derivative of a popular supplement
used to relieve arthritis, and a chemical that does not occur naturally during
Heparin production. Additionally, the FDA investigation revealed more
information about inadequate testing and supply-chain issues associated with
the Baxter Heparin.
Raw Heparin is often processed by small, unregistered "mom-and-pop"
workshops inChina. However, the key to establishing causation in the Scott
case, despite all of the issues with unsanitary conditions, etc., will be
Baxter's failure to perform a chemical test on the Heparin which would have
been sensitive enough to identify the difference between Heparin and OSCS.
The abhorrent conditions inChina from where Heparin was being imported (and
the fact that the FDA was not doing significant inspections) required the need
for more sensitive testing.
According to the FDA's inspection, the Changzhou SPL Facility was unable
to provide FDA with any assurance "that processing steps used to manufacture
heparin sodium, USP are capable of effectively removing impurities." FDA also
found that the facility failed "to have adequate systems for evaluating the
suppliers of crude heparin materials, or the crude materials themselves, to
ensure that these materials are acceptable for use." Moreover, the methods
employed to test Heparin Sodium United States Pharmacopoeia (USP) had not been
verified to ensure suitability under actual conditions of use, and the
equipment used to manufacture the product was "unsuitable" for its intended
use.
China's Ministry of Commerce is now requiring local Heparin makers to
increase testing of raw materials, improve post-sale tracking and ensure that
their raw material comes from registered suppliers. This requirement follows
U.S. Congressional inquiries into the FDA's overseas inspection process.
The House Oversight and Investigations Subcommittee held a hearing on
April 15th of this year regarding the distribution of contaminated Heparin. A
follow-up hearing took place on April 22nd at which time the committee asked
FDA Commissioner Andrew von Eschenbach how the agency will address concerns
regarding its efforts to inspect foreign drug facilities.
Mr. Scott has been appointed special administrator of his wife's estate
and, as such, is seeking personal and pecuniary damages from Baxter
International Inc. for the loss of his wife in a sum in excess of the minimal
jurisdictional limits of the Cook County Circuit Court.
Nolan Law Group is aChicago-based personal injury law firm concentrating
in aviation accidents, construction accidents, brain injury litigation,
medical malpractice, premises liability, product liability, and trucking
accidents.
SOURCE Nolan Law Group
Copyright © 2008, PRNewswire
Copyright © 2008, NewsBlaze,
Daily News
Tags: Healthcare, Pharmaceuticals, Biotechnology, iowa, Legal, Law and Lawyers, illinois
_ _Is your favorite bookmark site missing?
Ask for it.